Press Releases

Current Articles | Categories | Search | Syndication

29 October 2014  Joanne Hunter
RANDOX LAUNCHES WORLD’S MOST COMPREHENSIVE THIRD PARTY HAEMATOLOGY CONTROL
By Joanne Hunter @ 12:18 :: 12 Views

Randox Laboratories has launched a third party multi-analyte haematology control; the most comprehensive haematology quality control (QC) solution on the market to date.

Read More

29 October 2014  Joanne Hunter
Key opinion leaders provide an insight into best practice in acute cardiac care
By Joanne Hunter @ 10:46 :: 11 Views

Radiometer, a leading provider of technologically advanced acute care testing solutions, is pleased to announce the publication of Excellence in acute cardiac care, a supplement to the European Heart Journal: Acute Cardiovascular Care.

Read More

29 October 2014  Joanne Hunter
Radiometer launches new Acute Care Testing handbook
By Joanne Hunter @ 10:36 :: 11 Views

Radiometer has released a new Acute Care Testing handbook designed to support decision-­making processes in acute and high dependency settings. Available as either a printed handbook or eBook, it is intended as a supplement to comprehensive text books, offering a straightforward guide to a variety of acute care blood tests.

Read More

28 October 2014  Joanne Hunter
Faecal Calprotectin Sample Collection and Extraction Made Easy New CALEX® Cap is Quick, Clean and Consistent
By Joanne Hunter @ 09:43 :: 18 Views


Users of the BÜHLMANN range of Faecal Calprotectin Assays can now improve efficiency and laboratory workflow with the unique, new, CALEX® Cap sample collection and extraction device. 

Read More

21 October 2014  Joanne Hunter
New alpha+ Pipettes Great Performance at a Great Price
By Joanne Hunter @ 09:17 :: 72 Views


For unsurpassed pipetting accuracy at a very affordable price you can’t beat the new alpha+ pipettes from Alpha Laboratories (Eastleigh, UK). With an attractive modern design these lightweight, easy-to-use pipettes are robust and reliable even in the most challenging environments. The range includes variable and fixed volume single channel, plus 8- and 12-channel models. 

Read More

17 October 2014  Rebecca Bellars
Abbott's RealTime High Risk HPV Test is Now Available in Europe for Primary Screening for Cervical Cancer
By Rebecca Bellars @ 15:11 :: 102 Views



Abbott's DNA test for the detection of high-risk human papillomavirus (HR HPV) is now available in Europe as an important tool for first-line screening. The test is able to identify women at increased risk for development of cervical cancer or the presence of high-grade disease.

Read More

16 October 2014  Joanne Hunter
Appointment of Non-Executive Director
By Joanne Hunter @ 12:10 :: 96 Views


16 October, 2014 – The Board of Proteome Sciences is pleased to announce the appointment of Mr. Martin Diggle as a Non-Executive Director with immediate effect.

Read More

09 October 2014  Joanne Hunter
Roche Acquires Rights to Technology and Patent Applications from AbVitro to Support Next-Generation Sequencing Pipeline
By Joanne Hunter @ 14:03 :: 135 Views

Pleasanton, CA, USA,  October 9, 2014 / B3C newswire / - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it made a technology acquisition from AbVitro Inc, a company focused on therapeutic target discovery. Roche obtained exclusive rights to a primer extension based target enrichment technology and associated patent applications filed by AbVitro.  Under the terms of the agreement, AbVitro and Roche scientists will collaborate on the development and application of the technology.

Read More

09 October 2014  Joanne Hunter
Randox TxB Cardio Assay gains CE Approval
By Joanne Hunter @ 11:17 :: 124 Views

Global diagnostics company Randox Laboratories has secured CE marking for their TxB Cardio Assay. TxB Cardio is used to measure the effectiveness of aspirin (ASA), a drug which is used therapeutically around the world for its blood thinning properties. Clinical studies have shown that up to 25-30% of all patients who regularly take low doses of the drug are resistant to its full affects, meaning that these patients are at a considerably increased risk of a future cardiovascular event.

Read More

30 September 2014  Joanne Hunter
UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30th JUNE 2014
By Joanne Hunter @ 10:28 :: 140 Views

HIGHLIGHTS 

  • Commercial

o   Strong underlying growth in biomarker services

o   TMT® reagents sales increased 98%

o   Blood test predicting progression from MCI to Alzheimer’s Disease (AD)

o   Biological results underline performance of CK1d compounds reducing tau damage

o   SysQuant® coverage increased 4-fold to over 23,000 phosphorylation sites

o   SysQuant® delivered outstanding results in pancreatic cancer and in Alzheimer’s – CK1d compounds

Read More

Previous Page | Next Page